600196:SSEShanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A Analysis

Shanghai Fosun Pharmaceutical (600196) is trading at CNY 25.55, comfortably below its 20‑day SMA of 26.21 and the 50‑day SMA of 26.82, indicating a short‑term bearish bias. Technical indicators reinforce this view: RSI sits at 39.6 (neutral‑to‑oversold), MACD is bearish, and the price is approaching the identified support at CNY 24.92 while still below the resistance of CNY 27.44. Fundamentally, the stock appears overvalued given the DCF fair value of only CNY 8.65 versus the current price, despite a PE ratio of 20.6 that is modestly below the industry average of 26.2. Revenue has contracted 5.5% year‑over‑year, free cash flow is negative, and the debt‑to‑equity ratio of 60% signals a leveraged balance sheet, although operating cash flow remains positive and the dividend yield of 1.25% is supported by a low payout ratio of 26%. Recent material news highlights a strategic partnership with Pfizer on GLP‑1 therapies and steady growth in innovative‑drug revenue exceeding CNY 6.7 billion, which could improve future margins. However, the company faces medium regulatory risk in the Chinese pharma sector and a moderate 30‑day volatility of 21%, while its beta of 0.09 suggests limited market‑wide price swings. Overall, the stock’s current price reflects optimism that may be premature given the earnings slowdown and cash‑flow constraints, making the near‑term outlook cautious despite a solid dividend and long‑term growth catalysts.